Royal Fund Management’s Traws Pharma TRAW Stock Holding History

Royal Fund Management’s Portfolio TRAW Stock Details TRAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-40	Closed	-$14K	–	201
2021 Q1	$14K	Buy	+40	New	+$15.1K	﹤0.01%	183

Other funds holding TRAW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SFI

Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BPA

Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return

Royal Fund Management's TRAW Position: Q2 2021 in Review

Royal Fund Management sold out of Traws Pharma (TRAW) in Q2 2021, closing a stake of 40 shares — an estimated $14K sold.

Royal Fund Management first reported a position in TRAW in Q1 2021 and held it in 1 quarter. The position peaked at $14K in Q1 2021. 25 funds tracked by Wall St. Rank hold TRAW as of Q2 2021.

Royal Fund Management reported no remaining Traws Pharma position as of Q2 2021 after selling out during the quarter.
Royal Fund Management sold 40 Traws Pharma shares in Q2 2021, an estimated $14K.
Royal Fund Management first reported a position in Traws Pharma in Q1 2021 and held it in 1 quarter.
Royal Fund Management's Traws Pharma position peaked at $14K in Q1 2021.
25 funds tracked by Wall St. Rank held Traws Pharma as of Q2 2021.

Based on Royal Fund Management's 13F filing for Q2 2021, filed 26 Jul 2021.